02.04.13
Helix BioMedix Strengthens IP with 4 Patents • Helix BioMedix, Inc., Bothell, WA, has been granted four new US and foreign patents, further strengthening the company’s intellectual property assets. The patents, which focus on dermatological health, include US Patent No. 8,071,555 B2, “Protective Skin Care Peptides;” European Patent No. 2027152, “Peptide Fragments for Inducing Synthesis of Extra Cellular Matrix Proteins;” Australian Patent No. 2006212922, “Antimicrobial Hexapeptides;” and Mexican Patent No. 288451, “Short Bio-Active Peptides for Cellular and Immunological Modulation.” “Helix BioMedix continues to develop new and innovative technology focused on our core capabilities in dermatology, anti-infectives, cosmeceuticals and personal care,” said Dr. Lijuan Zhang, senior director of R&D Innovation. “Our ongoing research into the vital functions of the human innate immunity system has led to the identification of a wide array of distinct peptide sequences. Innate immunity peptides act as a first line of defense in the skin and play a key role in the processes controlling infection, modulating inflammation, healing wounds and building tissue.” |